Partnerships, Licensing, Investments and M&A Deals and Trends for October 2018 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for October 2018 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare ...

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2018 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2018 12

2.2.1 AstraZeneca Enters into Co-development Agreement with Innate Pharma 12

2.2.2 Novartis to Acquire Endocyte 12

2.2.3 Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 13

2.2.4 Grunenthal Receives Rights for Nexium from AstraZeneca 13

2.2.5 Dragonfly Therapeutics Enters into Collaboration Agreement with Merck 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2018 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2018 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2018 17

3.1.1 Top M&A Deals in October 2018 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2018 – October 2018 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2018 20

3.2.1 Top Equity Offering Deals in October 2018 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2018 – October 2018 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2018 23

3.3.1 Top PE/VC Deals in October 2018 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2018 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2018 26

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016–October 2018 28

3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016–October 2018 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2018 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2018 – October 2018 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2018 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2018 – October 2018 35

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2018 – October 2018 36

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 37

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2018 38

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2018 38

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 39

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2018 – October 2018 40

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2018 – October 2018 41

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2018 – October 2018 42

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2018 – October 2018 44

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2018 45

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2018 45

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2018 46

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 47

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2018 47

5.1.1 Oncology – Deals of the Month 48

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2018 49

5.2.1 Central Nervous System – Deals of the Month 50

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2018 52

5.3.1 Infectious Diseases – Deals of the Month 53

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2018 55

5.4.1 Cardiovascular – Deals of the Month 56

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2018 58

5.5.1 Immunology – Deal of the Month 59

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, October 2018 60

5.6.1 Gastrointestinal – Deals of the Month 61

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, October 2018 62

5.7.1 Metabolic Disorders – Deals of the Month 63

6 Deal Summary by Geography 64

6.1 Pharmaceuticals & Healthcare, North America Deals, October 2018 64

6.1.1 North America – Deals of the Month 65

6.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2018 67

6.2.1 Europe – Deals of the Month 68

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2018 70

6.3.1 Asia-Pacific – Deals of the Month 71

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2018 72

6.4.1 Rest of the World – Deals of the Month 73

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 75

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2018 – October 2018 75

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2018 – October 2018 76

8 Further Information 77

8.1 Methodology 77

8.2 About GlobalData 78

8.3 Contact Us 78

8.4 Disclosure information 78

8.5 Disclaimer 79

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 ...

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2018 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2018 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2018 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2018 – October 2018 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2018 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2018 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2018 – October 2018 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2018 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2018 – October 2018 29

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 30

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 34

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 – October 2018 36

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2018 – October 2018 37

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 38

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 39

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 40

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2018 41

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 – October 2018 43

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 44

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2018 45

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2018 45

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2018 46

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 48

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 50

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 53

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 56

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 59

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 61

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 63

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 65

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 68

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 71

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 73

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 75

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 76

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 10

Figure ...

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2018 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2018 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2018 – October 2018 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2018 – October 2018 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2018 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2018 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 28

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 30

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 – October 2018 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 – October 2018 36

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 37

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 38

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 39

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 40

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 – October 2018 41

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2018 – October 2018 42

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2018 – October 2018 43

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 44

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 47

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 49

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 52

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 55

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 58

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 60

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 62

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 64

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 67

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 70

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 72

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 75

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2018 – October 2018 76

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

GlobalData's Pharma eTrack is like having another FTE available to create our first-pass market assessments, at a fraction of the cost

  Glenmark Pharmaceuticals, Inc. USA